The Endocrine Disrupter Screening and Testing Advisory Committee has recommended the female pubertal onset assay as a Tier I test to detect potential endocrine-disrupting chemicals (EDs). We evaluated this assay's ability to detect EDs acting through various mechanisms. In two similar experiments, weanling female rats were dosed for 20 days by gavage with vehicle (0.5% methocel) or the following test compounds (mg/kg/day): 17␤-estradiol (E 2 ; 0.1, 2, or 4), ketoconazole (KETO; 24, 50, or 100), finasteride (FIN; 20), testolactone (TL; 220), fadrozole (FAD; 0.6, 1.2, or 6.0) or 6-propylthiouracil (PTU; 240). In vehicle-treated females, mean age at pubertal onset, as evidenced by vaginal opening (VO), varied interexperimentally from 32.3 ؎ 1.6 days to 33.5 ؎ 1.8 days. At 0.1 mg/kg E 2 , age at VO was reduced slightly to 31.0 ؎ 1.6 days, but not significantly ‫.)50.0؍␣(‬ Higher E 2 doses (2.0 and 4.0) reduced age at VO to 28 days. KETO delayed VO, but this delay was significant only at 100 mg/kg (39.7 ؎ 2.4 days). FIN and TL had no effect on age at pubertal onset; however, FAD significantly delayed VO. PTU delayed VO to 34.2 ؎ 1.1 days and altered thyroid weight, histology, and hormone levels. With each compound, significant changes in age at VO were accompanied by decreased uterine or ovarian weights. Thus, although this assay did not detect TL or lower doses of E 2 (0.1 mg/kg) or KETO (< 50 mg/kg), it was capable of detecting EDs operating through a variety of mechanisms.
In accordance with mandates contained in the Food Quality Protection Act (1996) and the Safe Drinking Water Act (1996) , the U.S. Environmental Protection Agency (EPA) formed the Endocrine Disrupter Screening and Testing Advisory Committee (EDSTAC). EDSTAC was responsible for outlining a test strategy to evaluate the endocrine activity of chemicals and pesticides. In August 1998, EDSTAC recommended a list of Tier I screening assays to detect potential endocrine-disrupting chemicals. One of the recommended in vivo screening assays is the female pubertal onset assay, which uses vaginal opening as a biomarker of pubertal onset.
Vaginal opening normally occurs from 31.6 to 35.1 days of age in Sprague-Dawley rats (Clark, 1999) , with first ovulation usually occurring within the next 5 days (Allen and Doisy, 1924; Urbanski and Ojeda, 1988) . Because estradiol plays a key role in this process, precocious vaginal opening can occur with compounds having estrogenic activity, whereas delayed vaginal opening suggests either antiestrogenic or androgenic activity, or effects on steroid biosynthesis or breakdown. Compounds inhibiting thyroid function (Wilen et al., 1981) , hypothalamic function (de Mengido et al., 1989) , or the release of gonadotropins (van den Dungen et al., 1989) , prolactin (Advis et al., 1981) , or growth hormone (Ramaley and Phares, 1980) can be detected also. Because of the apical nature of this assay, it affords a good overall assessment of endocrine system function; however, other factors not specifically controlled by estrogen/androgen/thyroid status (e.g., rate of growth) can influence the time of pubertal onset (Carney et al., 1998) .
Although vaginal opening has been used as a biomarker for pubertal onset for many years (Allen and Doisy, 1924) , the female pubertal onset assay, under its current guise, has not been validated for specificity, sensitivity, or reproducibility across laboratories. According to the protocol suggested by EDSTAC, animals are dosed daily by oral gavage with test compound starting at weaning (21 or 22 days of age) for 20 days. Growth is monitored during the dosing period. When vaginal opening occurs, the ages and weights of the affected animals are recorded. Daily vaginal lavage of these animals may be included to determine the onset of estrous cyclicity and measurement of cycle length. On the last day of treatment, females are anesthetized with carbon dioxide, euthanized by decapitation, and serum samples are collected for hormone analyses. Serum thyroxine (T4) and thyrotropin (TSH) analyses are required, whereas serum triiodothyronine (T3), estradiol, and prolactin are optional. Reproductive organ weights are collected, and the thyroid, ovaries, and uterus are examined histologically.
In actuality, there are few previous studies that have used this protocol to conduct the female pubertal onset assay. In 1989, Gray et al. (1989) used a similar protocol to demonstrate that the pesticide methoxychlor, a weak estrogen agonist, significantly hastened the age at vaginal opening in Long-Evans rats. In experiments examining the role of prolactin in pubertal onset, Tozawa (1993) administered bromocriptine, a dopamine agonist that induces hypoprolactinemia, to female rats beginning at 22 days of age and reported a delay in vaginal opening. Accelerated vaginal opening was observed in 22-day-old female rats given 0.01% coumestrol in the diet (Whitten and Naftolin, 1992) . Although these studies share similarities with the proposed EPA assay protocol with regard to age at which dosing was initiated and dosing by the oral route, none of these studies follows the assay design precisely.
The objective of the present study was to evaluate the female pubertal onset assay for its ability to detect known endocrineactive chemicals. In females, pubertal onset is estrogen-dependent; thus, animals were exposed to 17␤-estradiol (E 2 ) in order to collect data on assay functionality and sensitivity. Agents that affect steroid availability by targeting different enzymatic steps in steroid biosynthesis were tested also. These chemicals included: ketoconazole (KETO), which is a broad-spectrum cytochrome P 450 inhibitor that blocks the steroid biosynthesis pathway at several points; finasteride (FIN), which inhibits the 5␣-reductase conversion of testosterone to the more potent androgen, dihydrotestosterone; and the aromatase inhibitors ␦1-testolactone (TL) and fadrozole (FAD), which block the conversion of C19 androgens to C18 estrogens. In accordance with previous work using 5␣-reductase inhibitors (Ojeda et al., 1984) , FIN was not expected to alter pubertal onset in juvenile female rats. Propylthiouracil (PTU), which induces hypothyroidism by inhibiting thyroid iodination, was included to verify that effects on thyroid function could be detected.
Dose selection for each of these compounds was based on previous scientific reports of endocrine-modulating effects. In the case of E 2 , Odum et al. (1997) reported that 0.1-0.4 mg/kg E 2 given to rats by oral gavage increased uterine weight after 3 days of exposure. Following oral administration of 24 mg/kg KETO to male rats for 30 days, there was a 28% decrease in sperm number, a 20% decrease in percent motile sperm, and an 80% increase in percent abnormal sperm (Vawda and Davies, 1986) . At 60 mg/kg, KETO suppressed steroid-dependent prostatic tumor growth in rats (Smith et al., 1985) . The dose of TL (220 mg/kg) was greater than that shown to inhibit aromatase in humans (Barone et al., 1979) , yet low enough that antiandrogenic effects were not expected (Vigersky et al., 1982) . FIN (20 mg/kg) has been shown to decrease dihydrotestosterone levels and reduce ventral prostate weight in rats after treatment for 28 days (Shao et al., 1993) . The doses of FAD were selected based on a previous report by Nunez et al. (1996) where the middle (1.2 mg/kg) and high doses (6.0 mg/kg) of FAD severely decreased the number of estrous cycles compared to control animals. The dose of PTU used to induce hypothyroidism was similar to doses used by Sandrini et al. (1991) and Bunick et al. (1994) . Given that the compounds used in this study have known endocrine-modulating effects, we hypothesized that alterations in the age at pubertal onset would be detected with each of the chemical treatments with the exception of FIN.
MATERIALS AND METHODS

Animals.
Litters of 14-day-old CD rats were received from Charles River Breeding Laboratories (Portage, MI) on two occasions for use in pubertal onset assays. Upon receipt, animals were housed together by litter in clear plastic cages for 7 days prior to the start of dosing. The animal room was maintained at approximately 22 Ϯ 3°C and the humidity was 40 -70%. There was a 12-h photoperiod and air flow was set at 12-15 changes/h. Prior to initiation of the study, animals were given a health examination by a veterinarian, and only healthy animals of the appropriate size were used for the study. At 21 days of age, the body weights of animals selected for inclusion in the study ranged from 38 -53 g for experiment 1 and 29 -50 g for experiment 2. At this time, rats were randomized and moved to stainless steel wire-mesh cages. During the study, feed (Certified Laboratory Rodent Chow No. 5002; Purina Mills, Inc., St. Louis, MO) and municipal tap water were available ad libitum.
Chemicals. FIN, PTU, and E 2 were purchased from Sigma Chemical Company (St. Louis, MO). KETO was obtained from ICN Biomedicals (Costa Mesa, CA) and TL was purchased as a pharmaceutical preparation (Teslac; Bristol-Myers-Squibb; Princeton, NJ). FAD was generously donated by Novartis Pharmaceuticals Corporation (Summit, NJ). The estimated purity of each compound was determined by the chemical supplier.
Experimental design.
In the first series of experiments, 10 litters, each containing 12 pups and one lactating dam, were used. Each litter was composed of six males and six females, so that both male and female pubertal onset assays could be conducted simultaneously. (The results of the male assay will be presented separately.) In the second series of experiments, 10 litters containing 10 female pups per litter were used. At weaning (21 days of age), pups were randomized into treatment groups using a computer program designed to generate approximately equal mean body weights within each treatment group. Ten weanling female CD rats were assigned to each treatment group. Recently, EDSTAC has recommended 15 animals per treatment group, but group size was ambiguous at the time these experiments were designed. Prior to randomization, the animals were blocked by litter to ensure that siblings were not assigned to the same treatment group. This randomization scheme allowed us to control for two confounding factors: body weight and litter effect. At the time of randomization of weanlings, lactating dams were euthanized by carbon dioxide inhalation.
Based on EPA recommendations for the female pubertal onset assay, oral dosing was selected as the route of exposure. This also is consistent with potential human exposure to synthetic chemicals through accidental ingestion during chemical manufacture or use, or consumption of trace contaminants in foodstuffs. Test compounds were administered by gavage in 0.5% METHO-CEL A4M such that a dose volume of 3 ml/kg body weight yielded the appropriate dose.
Weanling female rats were administered test compounds by oral gavage daily from 21 through 40 days of age. As mentioned previously, dose levels for the various compounds were selected from literature reports citing changes in endocrine parameters.
Observations. Throughout the study, all animals were observed at least once daily for clinical signs of toxicity related to chemical treatment. Weanling body weights were measured daily and recorded for statistical analysis at 21, 27, 34, and 41 days of age. Body weight gains also were evaluated at the intervals 21-27, 27-34, and 34 -40 days of age. Dose volumes were adjusted daily based on body weights.
Each animal was examined starting at 28 days of age for vaginal patency. On the day that vaginal opening was first detected, the age and weight of the affected rats were recorded. Examinations continued until the rats had achieved vaginal patency or until 41 days of age, when the animals were necropsied. If an animal had not attained vaginal opening at 40 days of age, it was arbitrarily assigned a value of 41 days of age for age at vaginal opening. These artificial values were applied to 10% of the animals in the 50 mg/kg/day KETO group; 70% of the animals in the 100 mg/kg/day KETO group; and to 20, 20, and 70% of the animals in the 0.6, 1.2, and 6.0 mg/kg/day FAD groups, respectively.
Pathology.
Approximately 24 h after the final dose was administered, all animals were weighed, euthanized by carbon dioxide inhalation and given a limited gross necropsy with a focus on reproductive organs. Terminal serum samples from the control and PTU-treated animals were collected and analyzed for T 4 and TSH using radioimmunoassays. Hormone assays were conducted by Anilytics, Inc. (Gaithersburg, MD). The ovaries and uteri were removed and weighed. Uterine wet weight (including uterine fluid) was measured. Thyroid glands were removed, fixed in neutral, phosphate-buffered 10% formalin, weighed, and examined histologically. Other tissues were not examined microscopically.
Statistical evaluation.
Because there was a significant difference between the initial body weights of animals in experiments 1 and 2, data were analyzed statistically within each experiment. That is, in experiment 1, which had five distinct test compounds (see Results section), treatment groups were compared with the concurrent experiment 1 control group. In experiment 2, which had multiple dose groups per test compound, data were grouped by compound (E 2 , KETO, and FAD) and compared with the experiment 2 control group. Within each experiment, animals were randomized such that mean body weights and variances within each treatment group were similar at the time of weaning, thereby minimizing the impact of this variable on study outcome and analysis. Using this design, body weights, body weight gains, absolute and relative organ weights, and hormone levels were evaluated by Bartlett's test for equality of variances (Winer, 1971) . Based on the outcome of Bartlett's test, a parametric or nonparametric analysis of variance (ANOVA) was performed (Hollander and Wolfe, 1973; Steel and Torrie, 1960) . Age at vaginal opening was evaluated by nonparametric ANOVA. If the ANOVA was significant, analysis by Dunnett's test or the Wilcoxon Rank-Sum test with Bonferroni's correction was performed, respectively (Hollander and Wolfe, 1973; Winer, 1971) . Both Dunnett's test and Bonferroni's correction correct for multiple comparisons to the control group to keep the experiment-wise alpha at 0.05. The level of statistical significance was set a priori at ␣ ϭ 0.05.
RESULTS
Observations, Body Weights, and Body Weight Gains
During daily clinical observations, it was noted that two rats in the high dose KETO group and two rats in the TL group exhibited signs indicative of treatment-related toxicity. These effects, which included ungroomed appearance, decreased fecal output, altered fecal consistency, and excess salivation, were minor and transient (lasting Յ 2 days), and therefore were not expected to dramatically impact pubertal onset. There were no signs of toxicity in the other treatment groups with the exception of reduced body weights and body weight gains with some treatments (Figs. 1 and 2 ). Animals receiving 220 mg/kg TL had a transient decrease in body weight gains when dosing was initiated on days 1-7 and the PTU-treated animals had significantly lower body weights and body weight gains at each of the time points measured (Fig. 1) . In the mid-and high-dose E 2 groups, animals failed to gain weight at the same rate as control animals (Fig. 2) , remaining approximately 21% below controls at 27 days of age, 27% below controls at 34 days of age, and 29% below controls at 41 days of age. KETO treatment reduced body weights and body weight gains significantly in the high-dose group on dosing days 1-14 (Fig. 2) . Other treatments had no significant effects on body weights or body weight gains at the time points analyzed.
Vaginal Patency
In these experiments, examination of animals for vaginal opening began at 28 days of age and continued until this end point was achieved or until 41 days of age, when the animals were necropsied. The control animals in experiment 1 and experiment 2, despite differing significantly in body weight at the time dosing was initiated, achieved vaginal opening at similar ages. The mean age at vaginal opening was 32.3 Ϯ 1.6 days for control animals in experiment 1 compared with 33.5 Ϯ 1.8 days in experiment 2 (Fig. 3) . Although there was no significant difference in the age at vaginal opening, the weight at which vaginal opening occurred in these animals differed significantly (119.2 Ϯ 11.8 in experiment 1 vs 104.6 Ϯ 9.3 in experiment 2; Fig. 4) . Because of the significant differences in body weights across the two experiments, data were analyzed within each experiment by comparing all end points with the concurrent control group.
In order to evaluate the detection of precocious puberty and the sensitivity of the assay for estrogenic compounds, animals were exposed to 0.1, 2.0, or 4.0 mg/kg E 2 . Compared with concurrent controls, mean age at vaginal opening was reduced slightly (1.3 days) by treatment with low dose E 2 , but this difference was not significant (Fig. 3) . However, E 2 accelerated pubertal onset from 33.5 Ϯ 1.8 days of age in control animals to 28.1 Ϯ 0.3 and 28.5 Ϯ 0.5 days of age for animals dosed with 2.0 and 4.0 mg/kg E 2 , respectively. The first time point at which vaginal patency was evaluated was 28 days of age. Although not statistically different, animals treated with 0.1 mg/kg E 2 had lower body weights at the time that vaginal patency was achieved (106.8 Ϯ 7.1 g compared with 119.2 Ϯ 11.8 g in control animals; Fig. 4 ). Mean body weights at the time of vaginal opening were significantly reduced for the higher doses of E 2 (Fig. 4) .
To examine the effects of steroid biosynthesis inhibitors on pubertal onset, rats were exposed to 24, 50, or 100 mg/kg KETO, a broad spectrum steroid biosynthesis inhibitor. Neither 24 nor 50 mg/kg significantly delayed vaginal opening; however, the highest dose significantly delayed the age at pubertal onset (Fig. 3) . At 24 mg/kg KETO, the weight at vaginal opening was lower (108.3 Ϯ 6.1 g compared with 119.2 Ϯ 11.8 g in control animals), a difference that was not statistically identified. There was no difference in mean body weight at vaginal opening at 50 mg/kg KETO (Fig. 4) . At 100 mg/kg KETO, the mean body weight at vaginal opening was significantly greater than control animals (Fig. 4) . Neither FIN, a 5␣-reductase inhibitor, nor TL, an aromatase inhibitor, altered the age or weight at vaginal opening. However, FAD, a highly specific aromatase inhibitor, significantly delayed vaginal opening at all dose levels tested (Fig. 3) and increased mean body weight at vaginal patency in a dose-dependent manner (Fig. 4) .
To examine the role of the thyroid gland in pubertal onset, animals were given the thyroid inhibitor PTU. PTU (240 mg/kg) delayed the age and significantly reduced the weight at vaginal opening to 34.2 Ϯ 1.1 days of age and 102.9 Ϯ 6.2 g, respectively, compared with 32.3 Ϯ 1.6 days of age and 119.2 Ϯ 6.2 g in control animals.
Organ Weights and Thyroid Hormone Levels
After 20 days of dosing, animals were euthanized and ovarian, uterine, and thyroid weights were collected (Table 1) . At 2.0 and 4.0 mg/kg E 2 , there were significant decreases in terminal body weights (Table 1 ) and absolute and relative ovarian weights (Table 1) . A slight decrease in thyroid weight was statistically identified at 2.0 mg/kg E 2 , but this result was considered spurious based on the lack of a dose-response relationship and due to the finding that KETO, a steroid biosynthesis inhibitor, changed thyroid weights to a similar degree. Uterine weights were not significantly altered. At 0.1 mg/kg E 2 , there were no distinguishable treatment-related differences in organ weights compared with control animals.
With KETO treatment, there was a dose-dependent decrease in absolute and relative uterine weights at 50 and 100 mg/kg (Table 1 ). This decrease in uterine weight was significant only at the high-dose level. Ovarian weights were reduced with KETO treatment to 90% and 70% of control values at 50 mg/kg and 100 mg/kg, respectively. These changes were not statistically identified. There were no changes in reproductive organ or thyroid weights in the FIN or TL groups (Table 1) . Treatment with FAD significantly reduced uterine weight in a dose-dependent manner at all dose levels tested (Table 1) . Ovarian weights were slightly increased (approximately 25%) in FAD-treated animals, but not significantly.
The thyroid gland of every PTU-treated rat was grossly
FIG. 1.
Mean body weight gains of CD rats during treatment with various endocrine active compounds in Experiment 1. Body weights were monitored during the 20-day treatment period and body weight gains were analyzed statistically for the intervals 21-27, 27-34, and 34 -40 days of age. Animals in the PTU group (240 mg/kg) had significantly lower mean body weight gains at each of the time points examined. Body weight gains of TL-treated animals were decreased significantly from 21-27 days of age, but did not differ significantly from controls thereafter; n ϭ 10 animals per treatment group. identified as enlarged and thyroid gland weight was increased significantly (Table 1) . Absolute thyroid weights were increased 392% and relative thyroid weights were increased 567%. Absolute ovarian weights were decreased significantly to 61% of control values. PTU treatment did not significantly alter uterine weight. In conjunction with the changes in thyroid size, serum TSH levels were significantly increased with PTU treatment to 17.12 Ϯ 2.81 ng/ml compared with 0.29 Ϯ 0.13 ng/ml in control animals. Serum T4 levels were reduced significantly in PTU-treated animals to values well below 1.0 g/dl, the lowest standard curve value analyzed. The serum T4 level in control animals was 3.43 Ϯ 1.13 g/dl.
Histopathology
In this study, only the thyroid glands were examined histologically. The thyroid glands of all PTU-treated females had severe hyperplasia and severe thyroid follicular cell hypertrophy. There was slight individual thyroid follicular cell necrosis in these animals. In the TL-treated females, there was also slight thyroid follicular cell hypertrophy. No other treatmentrelated findings were observed.
DISCUSSION
This series of experiments was designed to evaluate whether the female pubertal onset assay could detect compounds that alter endocrine function through receptor-and nonreceptormediated events. Immature female rats exposed to E 2 experienced precocious vaginal opening, whereas treatment with KETO or FAD significantly delayed this process. PTU induced a small delay (Ͻ 2 days), whereas FIN and TL did not affect the age at which vaginal patency was achieved. Thus, in support of the EDSTAC proposal, the female pubertal assay was capable of detecting endocrine active chemicals that operate through a variety of mechanims.
Although not required by EDSTAC, multiple dose levels of E 2 , KETO, and FAD were used in this study in order to gauge the dose levels required to detect altered endocrine activity. According to EDSTAC, only one high dose (at or just below the MTD or limit dose) is required during Tier I testing with this assay (EDSTAC Final Report, 1998) . Consequently, the ability of this assay to detect most of these compounds at high dose levels may be sufficient for initial confirmation of assay
FIG. 2.
Mean body weight gains of CD rats during treatment with various endocrine active compounds in Experiment 2. Body weights were monitored during the 20-day treatment period and body weight gains were analyzed statistically for the intervals 21-27, 27-34, and 34 -40 days of age. Animals in the midand high-dose E 2 groups (2.0 and 4.0 mg/kg) had significantly lower mean body weights and body weight gains at all time points evaluated. Furthermore, the-high dose KETO group (100 mg/kg) had significant reductions in body weight gains from 21-34 days of age; n ϭ 10 animals per treatment group.
performance. However, because the compounds used in this study were pharmaceutical agents previously reported to alter endocrine function, there is an opportunity to view these assay results in the broader context of other scientific findings. This allows one to examine the correlation between a positive female pubertal assay and alterations in other parameters of endocrine function.
In order to evaluate the ability of this assay to detect estrogenic compounds, weanling rats were exposed to various concentrations of E 2 . Consistent with effects previously reported with estradiol treatment (Piacsek and Streur, 1975) , animals experienced significant acceleration in the age at vaginal opening, and vaginal opening occurred at body weights that were more than 30% lighter than corresponding control animals following treatment with 2.0 and 4.0 mg/kg/day E 2 . Furthermore, these high E 2 doses significantly reduced terminal body weights and ovarian weights, effects reported previously with E 2 treatment (Biegel et al., 1998; Dubuc, 1976) . Note that there were no significant differences in uterine weight at any dose of E 2 tested. Unlike the higher doses, the lowest dose of E 2 (0.1 mg/kg/day) did not alter the age at vaginal opening, weight at vaginal opening, or ovarian or uterine weights. In contrast, this dose of E 2 was capable of doubling uterine weight after 3 days of oral exposure to immature rats (Odum et al., 1997) .
FIG. 3.
Age at vaginal opening in CD rats following treatment with a variety of endocrine-active compounds. Animals were dosed by oral gavage beginning at 21 days of age and examined daily for vaginal opening beginning at 28 days of age. Bars indicate mean age at which vaginal opening was first detected (X Ϯ SD); *denotes values significantly different from the respective control group. Data were not compared across experiments, because control animals had significant differences in body weight at the initiation of dosing. n ϭ 10 animals per treatment group.
FIG. 4.
Body weights at the time of vaginal opening in CD rats following treatment with E 2 , steroid biosynthesis inhibitors, and PTU, a thyroid inhibitor. Rats were dosed with test compound starting at 21 days of age and examined for vaginal opening beginning at 28 days of age. Body weight was recorded on the day vaginal opening was first detected. Bars represent mean body weight at the time vaginal opening was detected (X Ϯ SD); *mark values significantly different from concurrent controls. Due to significant differences in the weanling body weights between control animals in experiments 1 and 2, treatments were compared with concurrent controls only; n ϭ 10 animals per treatment group.
With regard to non-receptor-mediated mechanisms, rats exposed to high-dose KETO (100 mg/kg/day) did not achieve vaginal patency until they were older and weighed more than their vehicle-treated counterparts. This difference in the weight at vaginal opening was most likely due to the advanced age of the KETO-treated animals when vaginal opening occurred. There was no suggestion of an overall effect on growth and development, because there were no significant differences in terminal body weights for animals in these dose groups compared with controls. Together, these data suggest a specific effect on vaginal opening or endocrine function that mediates pubertal onset, because delayed vaginal patency occurred independent from changes in body weight. Uterine weight was also significantly reduced in these animals. Interestingly, neither 24 nor 50 mg/kg/day caused significant changes in any of these parameters, despite a previous report that 24 mg/kg/day KETO administered orally for 30 days to male Wistar rats altered numerous sperm parameters (Vawda and Davies, 1986) . Heel et al. (1982) reported that female rats exhibited lower pregnancy rates and increased still births and pup mortality at KETO doses above 40 mg/100 g of food and increased pup malformations at 80 mg KETO/100 g of food. In our concurrent male pubertal assay, a significant decrease in epididymal weight was detected at the lowest KETO dose tested (24 mg/kg/day KETO; data not shown).
As predicted, the female pubertal assay did not detect FIN, a 5␣-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT). DHT is produced in such low quantities in female rats that inhibition of its synthesis has no bearing on normal female maturation and reproductive system function.
To examine the capacity of the female pubertal assay to detect aromatase inhibitors, we selected two compounds, FAD and TL. All doses of FAD effectively delayed vaginal opening and increased the body weight at vaginal opening, as well as significantly reduced uterine weight. This profile of effects was the same as those produced by high-dose KETO, consistent with the idea that both compounds reduced the levels of available estrogens. With FAD treatment, absolute and relative ovarian weights were increased slightly, but not significantly. Thyroid weights were not affected. These effects correlate with previous findings by Nunez et al. (1996) , whereby oral administration of FAD (Ն 0.8 mg/kg/day) to weanling female Sprague-Dawley rats delayed the onset of the first estrus and at doses of 1.2 mg/kg/day inhibited estrous cycling and vaginal cornification. In contrast to FAD, TL produced no significant changes in any of the end points monitored during this study. The dose of TL (220 mg/kg/day) was considered sufficient because this concentration, when based on body weight, exceeds by 10ϫ the clinical dosage recommended for females with breast cancer (1000 mg/day; Physician's Desk Reference, 1999). Furthermore, antiandrogenic effects (decreased epididymal weights and delayed preputial separation) were observed in juvenile male rats concurrently treated with this same concentration of TL (data not shown). Vigersky et al. (1982) have reported that TL is antiandrogenic at high doses. The inability of the female pubertal assay to detect TL is inexplicable. FAD is a more specific and more potent aromatase inhibitor, which may indicate a lack of sensitivity of the female pubertal onset assay to detect all but the most potent aromatase inhibitors. Alternatively, it is possible that female rats failed to respond to TL or simply overcame the aromatase inhibition with repeated exposure, a response that has been documented in humans with long-term TL treatment (Feuillan et al., 1993) . The thyroid antagonist PTU delayed the age at vaginal opening to 34.2 days of age, a modest delay of 1.9 days compared with concurrent controls, but a value that was not statistically identified and was still within the age range for vaginal opening in control rats from this strain. PTU significantly decreased the weight at vaginal opening by 14% and terminal body weights differed by 28% from control animals. The lack of a significant delay in pubertal onset with PTU differs from previous reports by Bakke et al. (1976) using neonatal rats and Wilen et al. (1981) using juvenile rats. In the study by Wilen et al. (1981) , vaginal opening was delayed significantly in Sprague-Dawley rats after treatment with 0.1% PTU in the diet (40.4 Ϯ 0.8 days of age with PTU treatment compared with 36.0 Ϯ 0.6 days of age in control animals). With PTU, growth rate from weaning to vaginal opening was reduced significantly to 2.5 Ϯ 0.1 g/day (4.9 Ϯ 0.1 g/day in controls; Wilen et al., 1981) . In the present study, growth rate was reduced, but the magnitude of the decrease was smaller (3.9 Ϯ 0.1 g/day compared with 6.0 Ϯ 0.2 g/day in control animals). In our study, thyroxine (T4) suppression by PTU was equivalent (or greater) than that reported by Wilen et al., where serum T4 measured 0.2-0.3 g/dl (Wilen et al., 1981) . Despite the modest effect on pubertal onset, PTU was readily detected as a thyroid inhibitor based on thyroid weights, histology, and serum T4 and TSH levels.
Although the female pubertal assay can detect chemicals that alter endocrine function through a wide variety of mechanisms, more data will be necessary to determine how readily this assay can be applied to the screening of synthetic chemicals with unknown endocrine activity. One factor that may complicate assay implementation is the considerable variability in the ages and weights at which vaginal opening occurs within a control population. Across the two experiments that make up this study, the mean age at vaginal opening differed by 1.3 days for control animals, a value that was not statistically different. Depending on the experiment, control animals underwent vaginal opening at mean ages of 32.3 or 33.5 days. This finding is within the normal range of ages for vaginal opening in Sprague-Dawley rats, which was 31.6 -35.1 (mean age: 33.4 Ϯ 0.77 days of age) (Clark, 1999) . However, animals in experiment 2 had significantly lower mean body weights than control animals in experiment 1 at the initiation of the study (15% lower), at the time of vaginal opening (12% lower), and at the termination of the study (15% lower). These results illustrate that small deviations in body weight, up to 12% in the present study, do not have a dramatic impact on the age at which vaginal opening occurs. Furthermore, given this interanimal variability for age and weight at vaginal opening, difficulties may arise in detecting significant treatment-related differences in the age and weight at pubertal onset. Note that at the time these experiments were conducted, the number of animals per treatment group was not clearly defined by the EPA. Since that time, a group size of 15 animals per treatment group has been suggested. Clark (1999) has reported that the statistical power of a pubertal onset assay to detect a 2-day change in the age at vaginal opening varies from 56% with 10 animals per treatment group to 75% with 15 animals per group; thus, the number of animals per treatment group can significantly enhance assay sensitivity.
Another complication may arise in distinguishing endocrinemediated effects from generalized delays in growth, which are not strictly mediated by the hypothalamic-pituitary-gonadal axis. According to the EDSTAC Final Report (1998), only one high dose of test compound (at or just below the MTD or limit dose) is required when conducting the female pubertal assay. If high doses of a chemical induce sufficient changes in growth rate concurrent with delayed vaginal opening, the issue of endocrine activity will be more difficult to resolve. This is a point recognized in the EDSTAC Final Report (1998), which states "If treatment reduces growth and delays vaginal opening, the mechanism responsible for the delay is always in question." Several previous studies have used feed restriction starting at weaning to investigate the impact of body weight on pubertal onset. In these studies, it was established that undernutrition can delay puberty (Glass et al., 1976; Glass and Swerdloff, 1980) . The data suggests that the relationship between body weight and vaginal opening is a continuum; that is, the greater the degree of body weight suppression, the more likely a delay in pubertal onset becomes. In the case of treatment with unknown chemicals, where the endocrine activity and toxicity are still under investigation, it may be difficult to interpret delays in pubertal onset when accompanied by decreased body weight.
